Stocks · News reference
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Kura Oncology, Inc. (KURA)
Filed: 2026-09-09 AccNo: 0001193125-26-385881 Size: 142 KB Item 8.01: Other Events
Kura Oncology Appoints Jennifer Fulk As CFO, Effective September 8
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.
HSBC Maintains Reduce on Eli Lilly, Raises Price Target to $940
HSBC analyst Rajesh Kumar maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.